INC280I
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2020 | $82,109 | 3 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $82,109 | 3 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A RANDOMIZED, OPEN LABEL, MULTICENTER PHASE II STUDY EVALUATING THE EFFICACY AND SAFETY OF CAPMATINIB (INC280) PLUS PEMBROLIZUMAB VERSUS PEMBROLIZUMAB ALONE AS FIRST LINE TREATMENT FOR LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER WITH PD-L1? | Novartis Pharmaceuticals Corporation | $82,109 | 0 |
Top Doctors Receiving Payments for INC280I
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Bradenton, FL | $82,109 | 3 |
Manufacturing Companies
Product Information
- Type Drug
- Total Payments $82,109
- Total Doctors 0
- Transactions 3
About INC280I
INC280I is a drug associated with $82,109 in payments to 0 healthcare providers, recorded across 3 transactions in the CMS Open Payments database. The primary manufacturer is Novartis Pharmaceuticals Corporation.
Payment data is available from 2020 to 2020. In 2020, $82,109 was paid across 3 transactions to 0 doctors.
The most common payment nature for INC280I is "Unspecified" ($82,109, 100.0% of total).
INC280I is associated with 1 research study, including "A RANDOMIZED, OPEN LABEL, MULTICENTER PHASE II STUDY EVALUATING THE EFFICACY AND SAFETY OF CAPMATINIB (INC280) PLUS PEMBROLIZUMAB VERSUS PEMBROLIZUMAB ALONE AS FIRST LINE TREATMENT FOR LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER WITH PD-L1?" ($82,109).